HomeTOP STORIESSangamo Therapeutics misses top-line and bottom-line estimates; reaffirms FY25 outlook Sangamo Therapeutics misses top-line and bottom-line estimates; reaffirms FY25 outlook By rogerjudd May 13, 2025 FacebookTwitterPinterestWhatsApp Post Content Previous articleSamsung launches ultra-thin Galaxy S25 Edge as Apple reportedly prepares iPhone AirNext articleU.S. reduces China ‘de minimis’ tariff rate to 54% from 120% latest articles The inflation process has shifted even as headline CPI declined – Federal Reserve Cerrado Gold reports Q4 results As H-1B Visa Program Changes, Skilled Foreign Workers Consider Leaving U.S. They Get Drunk Without Drinking: What It’s Like to Have Auto-brewery Syndrome Parents Who Borrowed for Children’s College Face Looming Deadline Watch: Artemis II’s journey so far… in 85 seconds explore more The inflation process has shifted even as headline CPI declined – Federal Reserve Cerrado Gold reports Q4 results As H-1B Visa Program Changes, Skilled Foreign Workers Consider Leaving U.S. They Get Drunk Without Drinking: What It’s Like to Have Auto-brewery Syndrome Parents Who Borrowed for Children’s College Face Looming Deadline Watch: Artemis II’s journey so far… in 85 seconds
